Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-03-20100CALL0 0107.58TRUE00
2026-03-20110CALL0 0129.76TRUE00
2026-03-20120CALL0 080.22TRUE00
2026-03-20130CALL0 0142.51TRUE00
2026-03-20140CALL0 0181.34TRUE00
2026-03-20150CALL0 0214.55FALSE00
2026-03-20160CALL0 0439.38FALSE00
2026-03-20170.55CALL1 178.5FALSE0.550
2026-03-20180.8CALL0 211392.76FALSE00
2026-03-20190.5CALL0 1090194.08FALSE00
2026-03-20200.3CALL0 480223.02FALSE00
2026-03-20211.15CALL0 5531.66FALSE00
2026-03-20220.3CALL0 5537.91FALSE00
2026-03-20230.15CALL0 6559.3FALSE00
2026-03-20240CALL0 0571.79FALSE00
2026-03-20250.6CALL0 180583.55FALSE00
2026-03-20300CALL0 0633.58FALSE00
2026-03-20350CALL0 0673.21FALSE00
2026-03-20100PUT0 0727.53FALSE00
2026-03-20110PUT0 0581.92FALSE00
2026-03-20120PUT0 0531.79FALSE00
2026-03-20130PUT0 0356.08FALSE00
2026-03-20140PUT0 0433.14FALSE00
2026-03-20151.4PUT16 113488.32TRUE0.60.75
2026-03-20161.3PUT0 222200.16TRUE00
2026-03-20171.5PUT0 1779.55TRUE00
2026-03-20182.5PUT0 18496.13TRUE00
2026-03-20193PUT0 120TRUE00
2026-03-20203.8PUT0 10TRUE00
2026-03-20210PUT0 00TRUE00
2026-03-20220PUT0 00TRUE00
2026-03-20230PUT0 0151.16TRUE00
2026-03-20240PUT0 00TRUE00
2026-03-20250PUT0 00TRUE00
2026-03-20300PUT0 0199.55TRUE00
2026-03-20350PUT0 00TRUE00
2026-04-1730CALL0 0312.04TRUE00
2026-04-1740CALL0 0255.26TRUE00
2026-04-1750CALL0 0212.96TRUE00
2026-04-1760CALL0 0189.28TRUE00
2026-04-1770CALL0 0159.93TRUE00
2026-04-17810.3CALL0 2134.7TRUE00
2026-04-1799.75CALL0 4112.44TRUE00
2026-04-17105.8CALL0 19297.95TRUE00
2026-04-17110CALL0 0103.79TRUE00
2026-04-17125.62CALL0 25275.78TRUE00
2026-04-17135.1CALL0 1999.02TRUE00
2026-04-17143.6CALL0 822135.48TRUE00
2026-04-17152.32CALL0 58133.39FALSE00
2026-04-17162.36CALL0 35293.46FALSE00
2026-04-17171.45CALL0 289129.16FALSE00
2026-04-17181.57CALL0 527300.54FALSE00
2026-04-17191CALL0 761256.76FALSE00
2026-04-17200.92CALL0 1298302.18FALSE00
2026-04-17210.45CALL0 2431127.62FALSE00
2026-04-17250.4CALL0 4402162.14FALSE00
2026-04-17300.24CALL0 462274.41FALSE00
2026-04-17350.2CALL0 1058420.67FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1740PUT0 00FALSE00
2026-04-1750PUT0 01018.46FALSE00
2026-04-1760PUT0 0852.85FALSE00
2026-04-1770PUT0 0720.26FALSE00
2026-04-1780PUT0 0606.11FALSE00
2026-04-1790PUT0 0522.73FALSE00
2026-04-17101.7PUT0 0448.25FALSE00
2026-04-17111.85PUT0 13386.76FALSE00
2026-04-17120.75PUT0 14142.56FALSE00
2026-04-17130.8PUT0 55201.47FALSE00
2026-04-17143.2PUT0 11272.25FALSE00
2026-04-17151.2PUT0 13946.55TRUE00
2026-04-17163.5PUT1 19127.7TRUE1.81.06
2026-04-17172.12PUT0 5175.05TRUE00
2026-04-17181.8PUT0 13275.44TRUE00
2026-04-17193.7PUT0 3079.09TRUE00
2026-04-17204.1PUT0 2166.84TRUE00
2026-04-17210PUT0 057.3TRUE00
2026-04-17257.6PUT0 20TRUE00
2026-04-173010.2PUT0 3114.98TRUE00
2026-04-17350PUT0 00TRUE00
2026-07-1730CALL0 0186.41TRUE00
2026-07-1740CALL0 0151.21TRUE00
2026-07-1750CALL0 0131.77TRUE00
2026-07-1760CALL0 0110.22TRUE00
2026-07-1770CALL0 097.19TRUE00
2026-07-1780CALL0 081.41TRUE00
2026-07-1790CALL0 089.6TRUE00
2026-07-17106.25CALL0 25111.04TRUE00
2026-07-17110CALL0 078.29TRUE00
2026-07-17125.9CALL0 1678.28TRUE00
2026-07-17136.9CALL0 379.32TRUE00
2026-07-17146.3CALL0 479.84TRUE00
2026-07-17155.61CALL0 981.55FALSE00
2026-07-17163.52CALL0 21157.63FALSE00
2026-07-17173.2CALL0 54363.63FALSE00
2026-07-17182.5CALL0 12173.02FALSE00
2026-07-17192.05CALL0 16179.65FALSE00
2026-07-17201.11CALL9 6273.62FALSE1.110
2026-07-17211.65CALL0 53102.86FALSE00
2026-07-17222.75CALL0 10266.17FALSE00
2026-07-17231.25CALL0 49201.44FALSE00
2026-07-17243CALL0 1205.99FALSE00
2026-07-17251CALL0 1723210.28FALSE00
2026-07-17300CALL0 0228.51FALSE00
2026-07-17350CALL0 0242.93FALSE00
2026-07-1730PUT0 00FALSE00
2026-07-1740PUT0 00FALSE00
2026-07-1750PUT0 00FALSE00
2026-07-1760PUT0 0531.27FALSE00
2026-07-1770PUT0 0421.42FALSE00
2026-07-1780PUT0 0354.48FALSE00
2026-07-1790PUT0 0305.77FALSE00
2026-07-17100PUT0 0267.19FALSE00
2026-07-17111.5PUT0 5235.03FALSE00
2026-07-17120PUT0 0207.24FALSE00
2026-07-17130PUT0 0100.89FALSE00
2026-07-17142.2PUT0 1160.04FALSE00
2026-07-17152.65PUT0 159.24TRUE00
2026-07-17162.3PUT0 873.36TRUE00
2026-07-17173.8PUT0 2166.74TRUE00
2026-07-17180PUT0 070.17TRUE00
2026-07-17194.1PUT0 174.09TRUE00
2026-07-17200PUT0 075.66TRUE00
2026-07-17210PUT0 073.03TRUE00
2026-07-17220PUT0 064.8TRUE00
2026-07-17230PUT0 069.23TRUE00
2026-07-17240PUT0 071.12TRUE00
2026-07-17250PUT0 087.68TRUE00
2026-07-17300PUT0 00TRUE00
2026-07-17350PUT0 00TRUE00
2026-10-1650CALL0 092.75TRUE00
2026-10-16100CALL0 077.59TRUE00
2026-10-16120CALL0 078.13TRUE00
2026-10-16130CALL0 077.56TRUE00
2026-10-16140CALL0 077.08TRUE00
2026-10-16150CALL0 075.63FALSE00
2026-10-16160CALL0 080.02FALSE00
2026-10-16174.3CALL0 3073.61FALSE00
2026-10-16180CALL0 084.03FALSE00
2026-10-16190CALL0 083.98FALSE00
2026-10-16200CALL0 088.89FALSE00
2026-10-16210CALL0 093.39FALSE00
2026-10-16220CALL0 097.53FALSE00
2026-10-16250CALL0 0108.32FALSE00
2026-10-16300CALL0 0176.48FALSE00
2026-10-1650PUT0 00FALSE00
2026-10-16100PUT0 0209.05FALSE00
2026-10-16120PUT0 094.55FALSE00
2026-10-16130PUT0 084.48FALSE00
2026-10-16140PUT0 080.46FALSE00
2026-10-16150PUT0 075.81TRUE00
2026-10-16160PUT0 079.39TRUE00
2026-10-16170PUT0 077.66TRUE00
2026-10-16180PUT0 075.2TRUE00
2026-10-16190PUT0 078.68TRUE00
2026-10-16200PUT0 074.89TRUE00
2026-10-16210PUT0 076.14TRUE00
2026-10-16220PUT0 078.1TRUE00
2026-10-16250PUT0 078.04TRUE00
2026-10-16300PUT0 077.1TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-1550CALL0 067.53TRUE00
2027-01-1588.5CALL0 265.07TRUE00
2027-01-15106.9CALL0 26668.36TRUE00
2027-01-15128.74CALL0 1082.12TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15154CALL3 2775.63FALSE40
2027-01-15174.52CALL0 46168.82FALSE00
2027-01-15202.6CALL47 32775.36FALSE-1.15-0.31
2027-01-15223.5CALL0 83127.53FALSE00
2027-01-15252.9CALL0 73136.59FALSE00
2027-01-15271.65CALL7 50278.66FALSE1.650
2027-01-15301.33CALL5 5378.48FALSE1.330
2027-01-15350CALL0 0158.14FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550.55PUT0 10FALSE00
2027-01-1580PUT0 0236.42FALSE00
2027-01-15102.45PUT0 52162.47FALSE00
2027-01-15120PUT0 0138.77FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15153PUT0 174.08TRUE00
2027-01-15170PUT0 077.41TRUE00
2027-01-15207.75PUT0 5378.31TRUE00
2027-01-15220PUT0 076.83TRUE00
2027-01-15250PUT0 076.91TRUE00
2027-01-15270PUT0 077.2TRUE00
2027-01-15300PUT0 078.9TRUE00
2027-01-15350PUT0 074.84TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 054.74TRUE00
2028-01-21811.51CALL0 260TRUE00
2028-01-21107.3CALL287 8168.19TRUE-0.6-0.08
2028-01-21126.22CALL69 7464.57TRUE-0.98-0.14
2028-01-21155.5CALL179 39169.82FALSE-0.8-0.13
2028-01-21175CALL1 133270.76FALSE50
2028-01-21204.2CALL578 178869.6FALSE-0.8-0.16
2028-01-21223.8CALL287 117669.59FALSE-1.3-0.25
2028-01-21253.5CALL739 69672.2FALSE-0.6-0.15
2028-01-21273.2CALL722 86272.07FALSE3.20
2028-01-21302.9CALL593 65773.03FALSE-0.2-0.06
2028-01-21352.5CALL214 99574.41FALSE2.50
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 0113.21FALSE00
2028-01-2180PUT0 0166.07FALSE00
2028-01-21102.7PUT0 6583.6FALSE00
2028-01-21123.22PUT0 3472.4FALSE00
2028-01-21154.75PUT0 2974.52TRUE00
2028-01-21170PUT0 076.31TRUE00
2028-01-21209PUT0 1080.21TRUE00
2028-01-212211PUT0 1079.56TRUE00
2028-01-212512.5PUT0 3080.72TRUE00
2028-01-21270PUT0 078.62TRUE00
2028-01-21300PUT0 077.94TRUE00
2028-01-21350PUT0 079.36TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm